uniQure (NASDAQ:QURE) Stock Price Down 15% Following Analyst Downgrade

uniQure N.V. (NASDAQ:QURE)’s share price dropped 15% on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $37.00 to $9.00. The Goldman Sachs Group currently has a neutral rating on the stock. uniQure traded as low as $8.78 and last traded at $8.9260. Approximately 2,917,063 shares traded hands during mid-day trading, an increase of 6% from the average daily volume of 2,757,464 shares. The stock had previously closed at $10.50.

A number of other equities analysts have also weighed in on QURE. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Tuesday, February 10th. TD Cowen reiterated a “buy” rating on shares of uniQure in a research report on Tuesday. Wolfe Research began coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, Chardan Capital dropped their price objective on shares of uniQure from $53.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, uniQure currently has a consensus rating of “Hold” and an average target price of $34.33.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 12,378 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $295,339.08. Following the completion of the transaction, the chief executive officer owned 639,076 shares of the company’s stock, valued at $15,248,353.36. This represents a 1.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christian Klemt sold 6,217 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total transaction of $148,337.62. Following the sale, the chief financial officer directly owned 211,513 shares in the company, valued at approximately $5,046,700.18. The trade was a 2.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 50,598 shares of company stock worth $1,248,588 over the last three months. 4.79% of the stock is owned by insiders.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

Institutional Trading of uniQure

A number of hedge funds have recently made changes to their positions in the company. Jefferies Financial Group Inc. acquired a new position in shares of uniQure in the second quarter valued at approximately $29,217,000. State Street Corp increased its position in uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the period. JPMorgan Chase & Co. raised its stake in shares of uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in uniQure during the 4th quarter worth about $33,062,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Price Performance

The firm has a market capitalization of $562.48 million, a P/E ratio of -2.62 and a beta of 0.73. The company has a fifty day moving average of $22.86 and a 200 day moving average of $29.72. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 230.98%. The company had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Sell-side analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.